Top 10 Trends in the Global Glucagon-Like Peptide-1 agonists Market Increasing demand for obesity treatment therapies Rising adoption of oral GLP-1 drugs Growth in personalized medicine approaches Expansion of combination therapies Increasing pharmaceutical R&D investments Rising prevalence of type 2 diabetes Growth in digital healthcare integration Expansion of next-generation peptide therapeutics Increasing use in cardiovascular risk management Rising focus on long-acting formulations Unlock Exclusive Market InsightsDownload the Brochure Now and Dive Deeper into the Future of the Global Glucagon-Like Peptide-1 Agonists Market
Timing and dosage adjustments Most of us have been prescribed a medication at one time or another that starts and finishes at the same dose
In 2025, the company reported a solid +8.37% YoY revenue growth, led by key growth brands: Entresto ($7.74B) continues to expand in heart failure treatment, Cosentyx ($6.66B) maintains strong demand in immunology across multiple indications, and Kisqali ($4.78B) is rapidly gaining traction in breast cancer, supported by expanding clinical data and adoption
Smart stimuli-responsive injectable gels and hydrogels for drug delivery and tissue engineering applications: a review
Key Products: Trevogrumab, anti-myostatin antibody designed to preserve lean muscle mass that was tested in combination with semaglutide to offset GLP-1-associated muscle loss
Current formulations of GLP-1 analogs rely primarily on subcutaneous injections, which may pose challenges to patient convenience and long-term adherence
